Mounjaro blood tests: what changes, what doesn't, and what to tell your doctor

Step 1: understand which blood markers tirzepatide actually shifts

Tirzepatide acts on two gut-hormone receptors, GIP and GLP-1, that are involved in blood-sugar regulation and appetite. That dual action shows up in blood work. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants on tirzepatide saw clinically significant reductions in HbA1c (a three-month average of blood sugar) and fasting glucose, even in those without type 2 diabetes at baseline. Lipid panels often improve too: LDL cholesterol and triglycerides tend to fall as body weight drops, though the picture varies by individual.

Liver enzymes, particularly ALT, can decrease as well, a reflection of reduced fat in the liver for people who carry it. These are, broadly speaking, favourable changes. But they are changes. If a GP or occupational health team runs bloods partway through your treatment without knowing you are on tirzepatide, a lower HbA1c or a shifted lipid profile might prompt questions. Telling them in advance saves a follow-up conversation.

Amylase and lipase (two enzymes the pancreas produces) can be mildly elevated in some people on GLP-1 class medicines. In most cases this is asymptomatic and does not indicate pancreatitis. Pancreatitis itself is a more serious event with distinct symptoms: severe, persistent stomach pain that may radiate to the back. If that happens, seek urgent medical help and read the NHS patient information for tirzepatide on when to call 999.

Step 2: know what a blood test will not detect

A question the prescribers at our clinical team hear regularly: will Mounjaro show up on a standard blood test or a workplace drugs screen? The short answer is no. Tirzepatide is not a controlled substance, it is not an opiate, a stimulant, a cannabinoid or any of the categories that routine drugs panels screen for. It will not trigger a positive.

Nor does a standard full blood count or metabolic panel include an assay for tirzepatide itself. Specialist pharmacokinetic testing can detect the drug (that is how clinical trials confirm adherence) but that is not something encountered in everyday healthcare. If you are ever asked by an employer or insurer about prescription medicines, the right answer is simply to disclose your prescription. There is nothing to conceal. More detail on what tirzepatide shows and doesn't show on a blood test is covered in our dedicated explainer.

Kidney markers are worth a separate mention. Creatinine and eGFR can look worse temporarily if you are significantly dehydrated, something that can happen during the early weeks of treatment when nausea is most pronounced. The drug is not directly nephrotoxic at therapeutic doses, but the side effects can be. Staying well hydrated, particularly around dose increases, is practical advice your prescriber will reinforce.

Step 3: tell the right people before any blood draw

The practical habit here is straightforward. Keep a note of your prescription in your phone or wallet alongside any other regular medicines. Before a blood test, tell the phlebotomist or requesting clinician you are on tirzepatide. This allows them to interpret results in context rather than chasing an unexpected finding.

If your GP is running annual bloods, the improvements in glucose and lipid markers are genuinely useful data. They document that treatment is working. Some patients find their GP is interested in supporting continued treatment once they see a liver enzyme normalising or an HbA1c dropping below the prediabetes threshold. The NHS England guidance on weight management injections specifically mentions GP notification as part of responsible prescribing, which is something every prescriber at nume, sorry, at our pharmacy follows as standard.

For transfers from another provider, or for anyone considering a dose increase, our guide to Mounjaro blood tests explains what evidence can strengthen a clinical assessment. At our free consultation, a GPhC-registered prescriber reviews your full health picture, not a form-processing algorithm. Current treatment options and associated pricing are set out on the weight-loss treatments overview.

One routine-friendly note: keeping your Mounjaro pen in the fridge door means you see it every morning, which also tends to prompt the habit of tracking how you feel, useful information if your prescriber asks about any side effects at review.

Step 4: use blood test results to guide ongoing treatment

Blood tests are not just a pre-treatment checkbox. They are a running record of how your body is responding. If lipid levels have normalised, your GP may want to review statin doses. If HbA1c has fallen dramatically, diabetes medications may need adjusting to avoid hypoglycaemia. These are conversations to have with the prescriber managing each condition, and if you are unsure how Mounjaro affects blood tests across different markers, our dedicated page covers the detail. Patients who experience persistent or unusual symptoms during treatment (anything beyond the expected early GI effects) should not wait for a scheduled review. Contact your prescribing team. Ours is available seven days a week. And if you ever notice a blood test result that surprises you in the context of treatment, our page on tirzepatide blood tests walks through what to look for and what the results mean, or you can get in touch directly.